Is ribociclib already included in medical insurance? How is it reimbursed by medical insurance?

Ribociclib (Ribociclib), as a targeted drug for the treatment of HR-positive and HER2-negative breast cancer, has been marketed in China and is included in medical insurance. The inclusion of ribociclib provides patients with more treatment options, especially in the treatment of advanced breast cancer. According to the latest medical insurance policy, the scope of medical insurance reimbursement for ribociclib is mainly for those patients who still need treatment after standard treatment, especially for patients with HR-positive breast cancer who use ribociclib combined with endocrine therapy.

Ribociclib's reimbursement in medical insurance is limited by the patient's specific treatment situation. According to the provisions of the National Medical Insurance Directory, ribociclib is suitable for certain disease groups, such as patients with advanced or metastatic breast cancer. Subject to meeting relevant conditions, the medical insurance reimbursement ratio of ribociclib can reach a certain proportion. The specific reimbursement amount needs to be confirmed according to the medical insurance reimbursement policies of different regions and hospitals. Some regions may have different reimbursement standards, and patients should consult local medical insurance and pharmacy staff when purchasing drugs.

Regarding drug prices, the original drug of ribociclib has been launched in China and has entered the medical insurance market at a relatively preferential price. The common specification is 200mg*63 tablets of ribociclib, which sells for about 4,000 yuan per box. However, it should be noted that although it is included in medical insurance, the actual payment amount of the patient is still affected by the medical insurance reimbursement ratio, personal medical insurance policy and local reimbursement policy.

At the same time, the price of ribociclib in overseas markets is relatively high, especially the European version of the original drug. The common specifications are 200mg21 tablets, 20 0mg42tablets and 200mg63tablets may cost as much as more than 20,000 yuan per box, while the original Indian version is priced at a relatively low price of about more than 2,000 yuan. In addition, generic drugs of ribociclib are also on the market and are relatively cheap. For example, the 200mg21 tablets produced by Lucius Pharmaceuticals in Laos are priced at more than 1,000 yuan per box. The ingredients of the drug are basically the same as the original drug, providing patients with a more economical choice.

Reference materials:https://us.kisqali.com/